Prostate cancer (advanced, hormone dependent) - degarelix depot [ID590]

Anticipated publication date:

Degarelix depot for treating advanced hormone dependent prostate cancer
 
Status
In development
Anticipated publication date
June 2015
Process
STA
Topic area
  • Cancer
  • Urogenital

Provisional Schedule

Closing date for invited submissions / evidence submission: 29 August 2013
1st appraisal committee meeting: 27 November 2013
2nd appraisal committee meeting 11 February 2014
3rd appraisal committee meeting: 12 November 2014
4th appraisal committee meeting: 06 May 2015

Project Team

Associate Director: Helen Knight
Technical Lead: Pilar Pinilla-Dominguez
Communications manager: Alice Law
Project manager:

Kate Moore

Technical Advisor: Fay McCracken

Consultees

Manufacturers/sponsors
  • Ferring Pharmaceuticals (degarelix)
Patient/carer groups
  • Prostate Cancer Support Federation
  • Prostate Cancer UK
Professional groups
  • British Association of Urological Surgeons
  • British Uro-Oncology Group
  • Cancer Research UK
  • Royal College of Nursing
  • Royal College of Physicians
  • Urology Foundation
Others
  • Department of Health
  • NHS Durham Dales, Easington and Sedgefield CCG
  • NHS England
  • NHS Southport and Formby CCG
  • Welsh Government

Commentators

General
  • Department of Health,Social Services and Public Safety for Northern Ireland
  • Healthcare Improvement Scotland
Comparator manufacturers
  • Accord Healthcare (bicalutamide) (Confidentiality agreement not signed, not participating)
  • AstraZeneca (bicalutamide, goserelin)
  • Bayer (cyproterone)
  • Bluefish Pharmaceuticals (bicalutamide) (Confidentiality agreement not signed, not participating)
  • Ferring Pharmaceticals (triptorelin)
  • Genus Pharmaceuticals (goserelin) (Confidentiality agreement not signed, not participating)
  • Glenmark Generics Europe (bicalutamide) (Confidentiality agreement not signed, not participating)
  • Ipsen (triptorelin)
  • Medac (bicalutamide) (Confidentiality agreement not signed, not participating)
  • Neolab (cyproterone) (Confidentiality agreement not signed, not participating)
  • Orion Pharma UK (histrelin)
  • Sanofi (buserelin)
  • Takeda UK (leuprorelin) (Confidentiality agreement not signed, not participating)
  • Teva UK (bicalutamide) (Confidentiality agreement not signed, not participating)
  • Wockhardt UK (cyproterone) (Confidentiality agreement not signed, not participating)
  • Zentiva (bicalutamide) (Confidentiality agreement not signed, not participating)
Relevant research groups
  • National Cancer Research Network
Evidence Review Group
  • School of Health and Related Research (ScHARR)
  • National Institute for Health Research Health Technology Assessment Programme
Associated Guideline Groups
  • National Collaborating Centre for Cancer
Associated Public Health Groups
  • None

Timeline

Key events during the development of the guidance

Date
Update
April 2015

Following the committee discussion on 12 November 2014, the decision support unit (DSU) have been commissioned to explore the estimates of the rate of spinal cord compression in people with metastatic hormone-dependent prostate cancer (and also specifically with spinal metastases from the prostate), in addition to the cost effectiveness of degarelix compared with the LHRH agonists in people with spinal metastases, if sufficient data are available. The next committee meeting for this topic will take place on Wednesday 06 May 2015.

September 2014

Following the release of the appeal decision, we have been working to arrange the committee meeting discussion for this topic, which is scheduled for 12 November 2014.

Get involved